Market Momentum Report: Lexicon Pharmaceuticals Inc (LXRX)’s Positive Close at 1.67

In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The price of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) closed at $1.67 in the last session, up 0.60% from day before closing price of $1.66. In other words, the price has increased by $0.60 from its previous closing price. On the day, 1.51 million shares were traded. LXRX stock price reached its highest trading level at $1.67 during the session, while it also had its lowest trading level at $1.61.


We take a closer look at LXRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.56 and its Current Ratio is at 15.58. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.36.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 17, 2024, initiated with a Buy rating and assigned the stock a target price of $10.

On April 30, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $5.

On March 07, 2023, Jefferies started tracking the stock assigning a Hold rating and target price of $3.Jefferies initiated its Hold rating on March 07, 2023, with a $3 target price.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 16 ’23 when COATS LONNEL bought 90,000 shares for $1.05 per share. The transaction valued at 94,797 led to the insider holds 914,359 shares of the business.

COATS LONNEL bought 10,000 shares of LXRX for $10,100 on Nov 10 ’23. The Chief Executive Officer now owns 824,359 shares after completing the transaction at $1.01 per share. On Oct 12 ’23, another insider, DEBBANE RAYMOND, who serves as the Director of the company, bought 148,820 shares for $1.03 each. As a result, the insider paid 153,805 and bolstered with 1,340,847 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 603691648 and an Enterprise Value of 161884384. For the stock, the TTM Price-to-Sale (P/S) ratio is 261.34 while its Price-to-Book (P/B) ratio in mrq is 1.42. Its current Enterprise Value per Revenue stands at 70.08 whereas that against EBITDA is -0.873.

Stock Price History:

The Beta on a monthly basis for LXRX is 1.36, which has changed by -0.28326178 over the last 52 weeks, in comparison to a change of 0.26253593 over the same period for the S&P500. Over the past 52 weeks, LXRX has reached a high of $3.73, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is -3.95%, while the 200-Day Moving Average is calculated to be -0.39%.

Shares Statistics:

According to the various share statistics, LXRX traded on average about 2.62M shares per day over the past 3-months and 2554040 shares per day over the past 10 days. A total of 361.49M shares are outstanding, with a floating share count of 351.32M. Insiders hold about 2.81% of the company’s shares, while institutions hold 62.59% stake in the company. Shares short for LXRX as of 1718323200 were 21566751 with a Short Ratio of 8.23, compared to 1715731200 on 23271956. Therefore, it implies a Short% of Shares Outstanding of 21566751 and a Short% of Float of 13.229999000000001.

Earnings Estimates

The stock of Lexicon Pharmaceuticals Inc (LXRX) is currently drawing attention from 6.0 analysts actively involved in the ongoing evaluation and rating process.On average, analysts expect EPS of -$0.19 for the current quarter, with a high estimate of -$0.14 and a low estimate of -$0.21, while EPS last year was -$0.22. The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.15 and low estimates of -$0.23.

Analysts are recommending an EPS of between -$0.62 and -$0.87 for the fiscal current year, implying an average EPS of -$0.75. EPS for the following year is -$0.61, with 6.0 analysts recommending between -$0.21 and -$0.75.

Revenue Estimates

For the next quarter, 5 analysts are estimating revenue of $8.96M. There is a high estimate of $17.06M for the next quarter, whereas the lowest estimate is $3.5M.

A total of 5 analysts have provided revenue estimates for LXRX’s current fiscal year. The highest revenue estimate was $40.13M, while the lowest revenue estimate was $14M, resulting in an average revenue estimate of $24.11M. In the same quarter a year ago, actual revenue was $1.2MBased on 6 analysts’ estimates, the company’s revenue will be $98.39M in the next fiscal year. The high estimate is $171.9M and the low estimate is $52.1M.

Most Popular